Jump Financial LLC Invests $1.98 Million in BioNTech SE Sponsored ADR $BNTX

Key Points

• Jump Financial LLC has invested approximately $1.98 million in BioNTech SE, acquiring 21,792 shares of the company's stock.
• Analyst ratings show a mixed outlook, with a consensus rating of "Moderate Buy" and an average target price of $135.80.
• BioNTech reported a quarterly loss of ($1.60) EPS, missing analyst estimates, despite revenue growth of 102.6% year-over-year.

Jump Financial LLC purchased a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 21,792 shares of the company's stock, valued at approximately $1,984,000.

A number of other institutional investors also recently bought and sold shares of BNTX. Banque Cantonale Vaudoise purchased a new position in BioNTech during the first quarter valued at approximately $36,000. Costello Asset Management INC purchased a new stake in shares of BioNTech during the first quarter worth approximately $91,000. Goodman Advisory Group LLC purchased a new stake in shares of BioNTech during the first quarter worth approximately $105,000. Whittier Trust Co. lifted its holdings in BioNTech by 3,846.2% in the 1st quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock valued at $187,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after buying an additional 713 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on BNTX shares. HC Wainwright decreased their target price on shares of BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. The Goldman Sachs Group began coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Truist Financial reissued a "buy" rating and issued a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Trading Down 1.9%

Shares of BNTX traded down $1.93 on Monday, hitting $100.00. 505,409 shares of the stock traded hands, compared to its average volume of 759,110. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.04 billion, a P/E ratio of -62.50 and a beta of 1.39. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $131.49. The stock's 50 day moving average is $109.66 and its two-hundred day moving average is $104.91.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. During the same quarter in the prior year, the company earned ($3.36) EPS. The firm's revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.